



Soanz® (torsemide) – New drug approval

- On June 14, 2021, the [FDA approved](#) Sarfex Pharmaceuticals' [Soanz \(torsemide\)](#), in adults for the treatment of edema associated with heart failure or renal disease.
- Torsemide is already available [generically](#) as a 5 mg, 10 mg, 20 mg, and 100 mg tablet.
 - Generic torsemide is approved for treatment of edema associated with heart failure, renal disease or hepatic disease and the treatment of hypertension, to lower blood pressure.
- Soanz is contraindicated in patients:
 - With known hypersensitivity to Soanz
 - Who are anuric
 - With hepatic coma.
- Warnings and precautions for Soanz include hypotension and worsening renal function, electrolyte and metabolic abnormalities, and ototoxicity.
- Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with Soanz.
- The recommended initial dose for Soanz is 20 mg orally once daily. If the diuretic response is inadequate, titrate upward by approximately doubling until the desired diuretic response is obtained. Doses higher than 200 mg have not been adequately studied.
- Sarfex Pharmaceuticals' launch plans for Soanz are pending. Soanz will be available as a 20 mg and 60 mg tablet.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.